Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia
Less than 40% of patients with newly diagnosed adult immune thrombocytopenia will show spontaneous recovery within 12 months. Therefore, second-line treatments are frequently used to maintain a hemostatic platelet count or at best to cure the disease, with as few adverse effects as possible. Neverth...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis Group
2020-04-01
|
| Collection: | Platelets |
| Sujets: | |
| Accès en ligne: | http://dx.doi.org/10.1080/09537104.2019.1636018 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|